Jump to content

IHCH-7179

From Wikipedia, the free encyclopedia
IHCH-7179
Clinical data
Other namesIHCH7179
Drug classSerotonin 5-HT1A receptor agonist; Serotonin 5-HT2A receptor antagonist; Dopamine D2 receptor partial agonist
ATC code
  • None
Identifiers
  • 1-(4-fluorophenyl)-4-(2,5,11-triazatetracyclo[7.6.1.02,7.012,16]hexadeca-1(15),9,12(16),13-tetraen-5-yl)butan-1-one
CAS Number
PubChem CID
Chemical and physical data
FormulaC23H24FN3O
Molar mass377.463 g·mol−1
3D model (JSmol)
  • C1CN2C(CC3=CNC4=C3C2=CC=C4)CN1CCCC(=O)C5=CC=C(C=C5)F
  • InChI=1S/C23H24FN3O/c24-18-8-6-16(7-9-18)22(28)5-2-10-26-11-12-27-19(15-26)13-17-14-25-20-3-1-4-21(27)23(17)20/h1,3-4,6-9,14,19,25H,2,5,10-13,15H2
  • Key:QNGJKKMQTDOCDJ-UHFFFAOYSA-N

IHCH-7179 is a serotonin and dopamine receptor modulator related to the ergolines.[1][2] It acts as a serotonin 5-HT1A receptor agonist, serotonin 5-HT2A receptor antagonist, and dopamine D2 receptor partial agonist.[1] The drug produces antipsychotic-like effects in rodents, such as prevention of the hyperlocomotion induced by the NMDA receptor antagonist dizocilpine (MK-801).[1] It also blocks the head-twitch response induced by the serotonergic psychedelic LSD.[1] IHCH-7179 was first described in the scientific literature by 2024.[1] It was developed by the Chinese Academy of Sciences and associated organizations in Shanghai, China.[1][2] IHCH-7179 is of interest for potential treatment of schizophrenia.[1][2]

See also

[edit]

References

[edit]
  1. ^ a b c d e f g Chen Z, Yu J, Wang H, Xu P, Fan L, Sun F, Huang S, Zhang P, Huang H, Gu S, Zhang B, Zhou Y, Wan X, Pei G, Xu HE, Cheng J, Wang S (April 2024). "Flexible scaffold-based cheminformatics approach for polypharmacological drug design". Cell. 187 (9): 2194–2208.e22. doi:10.1016/j.cell.2024.02.034. PMID 38552625.
  2. ^ a b c "Delving into the Latest Updates on IHCH-7179 with Synapse". Synapse. 8 May 2025. Retrieved 30 July 2025.